Dry eye disease (DED) is a common multifactorial disorder that perpetuates itself in a vicious circle of inflammation, tear film instability, neurosensory abnormalities, and hyperosmolarity resulting in an ongoing immune response.
This satellite symposium archive highlights the latest scientific findings on DED and the novel approaches currently under investigation to treat ocular surface disease.
Supported by an independent medical education grant from Oyster Point Pharma.
Upon completion of this activity, the participant should be able to:
Provided by Evolve Medical Education
Evolve Medical Education LLC (Evolve) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Evolve designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
In order to obtain credit, proceed through the program, complete the post-test, evaluation and submit for credit.
Noam Cohen, MD, PhD
Ralph Butler Professor
Division of Rhinology
Otorhinolaryngology - Head and Neck Surgery
Perelman School of Medicine at the University of Pennsylvania
Anat Galor, MD, MSPH
Professor of Ophthalmology
Bascom Palmer Eye Institute
Miller School of Medicine
University of Miami
Stephen C. Pflugfelder, MD
Professor of Ophthalmology
James and Margaret Elkins Chair
Director, Ocular Surface Center
Baylor College of Medicine
DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflicts of interest relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all conflicts of interest prior to this educational activity.
The following faculty/staff members have the following financial relationships with commercial interests:
Noam Cohen, MD, PhD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board: GlaxoSmithKline, Novartis, Oyster Point Pharma, and Sanofi/Regeneron. Founding Partner: 4 Sinuses. Patent Licensing Agreement: GeneOne Life Sciences. Research/Grant Support: National Institutes of Health (National Institute for Deafness and Other Communication Disorders) and Veterans Affairs.
Anat Galor, MD, MSPH, Anat Galor, MD, MSPH, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: AstraZeneca, Dompé, Novaliq, Novartis, Oyster Point Pharma, and Taurus.
Stephen C. Pflugfelder, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Dompé, Kala Pharmaceuticals, Novartis. Grant/Research Support: Dompé.
The Evolve staff, planners, and reviewers have no financial relationships with commercial interests.
OFF-LABEL STATEMENT
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve or Oyster Point Pharma.
Release Date:
Expiration Date:
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Yewlin E. Chee, MD
Camila Ventura MD, PhD
Edward Wood, MD
Tony Capone Jr, MD
Katherine E. Talcott, MD
Nassim Abreu, MD
Janis T. Eells, Ph.D.
David Boyer, MD
Diana V. Do, MD
Marion Munk, MD, Ph.D
